Metformin is the most recognized first choice drug for patients with type 2 diabetes mellitus
https://doi.org/10.21518/2079-701X-2018-4-20-27
Abstract
Many anti-diabetic drugs are now available to treat type 2 diabetes mellitus, including sulfonylureas, glinides, α-glucosidase inhibitors, thiazolidinediones, incretin-related drugs, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose co-transporter 2 (SGLT2) inhibitors and, certainly, metformin. It holds a central position, given its role in reducing hyperglycemia and the risk of life-threatening complications. The International Diabetes Federation annually confirms the appropriateness of the appointment of metformin as a first step in the treatment of type 2 diabetes mellitus along with lifestyle modification [1].
About the Author
A. M. Mkrtumyan
A.I.Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
MD, Prof
Russian Federation
MD, Prof
References
1. Atlas: www.idf.org/diabetesatlas.org IDF Diabetes Atlas 7th edition, 2015 online version of IDF.
2. Dedov II, Shestakova MV, Mayorov AYu. Standards for specialized medical care in diabetes mellitus. Issue 8, 2017: 31-33.
3. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin. An Update. Ann Intern Med, 2002, 137: 25–33.
4. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab, 2003 Sep, 29(4 pt 2): 6S28-355.
5. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med, 1997 Dec, 103(6): 491-497.
6. De Fronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab, 1991 Dec, 73(6): 1294-1301.
7. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: A meta-analysis. Diabetes Metab Rev, 1995, 11(Suppl 1): 57–62.
8. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care, 2010 Mar, 33(3): 501-506. doi: 10.2337/dc09-1749.
9. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med, 2011 May 3, 154(9): 602-613. doi: 10.7326/0003-4819-154-9-201105030-00336.
10. Russell-Jones D, Cuddihy RM, Hanefeld, M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drugnaive patients with type 2 diabetes (DURATION-4). A 26-week double-blind study. Diabetes Care, 2012, 35: 252–258.
11. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care, 2012, 35: 446–454.
12. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med, 2004, 256: 1-14.
13. Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Bosisio E. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovascular Pharmacology, 1984, 6: 914-923.
14. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol, 2001, 37: 1344–1350.
15. Agarwal N, Rice, SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab, 2010 February, 95(2): 722–730.
16. De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine, 2005, 257: 100–109.
17. Grant PJ. The effects of highand medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care, 1996 Jan, 19(1): 64-66.
18. Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, John WW, Peter JG. The effect of dimethylbiguanide on thrombin activity, F XIII activation, fibrin polymerization, and fibrin clot formation. Diabetes, 2002, 51: 189–197.
19. Kao J, Tobis J, Mc Clelland RL, Heaton MR, Davis BR, Holmes DR, Currier JW. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol, 2004, 93: 1347–50.
20. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail, 2010, 16: 200–206.
21. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail, 2011 Jan 1, 4(1): 53–58.
22. The Diabetes Prevention Program Research Group. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2012, 35(4): 731-737.
23. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care, 2010, 33(7):, 1674-1685.
24. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care, 2010, 33: 322–326.
25. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F.Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond), 2012 Mar, 122(6): 253-270.
26. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009, 32(9): 1620-1625.
27. Williamson RM, Price JF, Glancy S, et al. Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care, 2011, 34: 1139–1144.
28. Ivashkin VT, Maevskaya MV. Lipotoxicity and metabolic disorders in obesity. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii (RJGGK), 2010, 20b(1): 4-13.
29. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther, 2009 Jan, 29(2): 172-182.
Review
For citations:
Mkrtumyan AM. Metformin is the most recognized first choice drug for patients with type 2 diabetes mellitus. Meditsinskiy sovet = Medical Council. 2018;(4):20-27. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-20-27
Views:
1070
Email this article 